Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCX-899
- Development stage
- Discontinued
- Lead developer
- NicOx Research Institute
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NCX-899 is a nitric oxide (NO)-releasing derivative of the ACE inhibitor enalapril, developed by NicOx SA. It is a dual-action small molecule designed to inhibit the angiotensin-converting enzyme (ACE) while simultaneously acting as a nitric oxide donor. This hybrid pharmacological approach was intended to provide enhanced cardiovascular benefits by combining the blood pressure-lowering effects of ACE inhibition with the vasodilatory and anti-remodeling properties of nitric oxide. In preclinical studies, NCX-899 demonstrated superior efficacy compared to enalapril alone, showing improved cardiac function and prevention of unfavorable cardiac remodeling in models such as cardiomyopathic hamsters and spontaneously hypertensive rats. Despite these promising preclinical results, the development of NCX-899 has been discontinued.
- Other names
- enalapril nitroderivativeNO-enalapril
02
Targets
sGC (Soluble Guanylyl Cyclase)ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on NCX-899.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCX-899.